Bifogade filer
2024 10 04 Announcement nr 24 - UK Capital decrease
Kurs
+8,57%
Kurs
+8,57%
Open
0,21
High
0,24
Low
0,20
Close
0,23
Kursutveckling under dagen för detta pressmeddelande
(DKK).
Likviditet
0,84 MDKK
Likviditet
0,84 MDKK
Rel. mcap
0,39%
Antal aktier
3 913 838
Likviditet under dagen för detta pressmeddelande
Kalender
| Tid* | ||
| 2024-11-15 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-16 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-03 | - | Extra Bolagsstämma 2024 |
| 2024-05-16 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-17 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2024-04-16 | - | Årsstämma |
| 2024-03-20 | - | Bokslutskommuniké 2023 |
| 2023-11-02 | - | Extra Bolagsstämma 2023 |
| 2023-08-16 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-26 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2023-04-25 | - | Årsstämma |
| 2023-03-31 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Extra Bolagsstämma 2022 |
| 2022-08-31 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-26 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2022-04-25 | - | Årsstämma |
| 2022-03-31 | - | Bokslutskommuniké 2021 |
| 2022-01-21 | - | Bokslutskommuniké 2021 |
| 2021-11-10 | - | Extra Bolagsstämma 2021 |
| 2021-08-30 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-03 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2021-04-29 | - | Årsstämma |
| 2020-08-24 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-28 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2020-04-27 | - | Årsstämma |
| 2020-03-30 | - | Bokslutskommuniké 2019 |
| 2019-11-01 | - | Split PEG 10:1 |
| 2019-08-23 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-29 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2019-04-26 | - | Årsstämma |
| 2019-03-29 | - | Bokslutskommuniké 2018 |
| 2019-02-26 | - | Extra Bolagsstämma 2019 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-01 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2018-04-30 | - | Årsstämma |
| 2018-04-06 | - | Bokslutskommuniké 2017 |
| 2017-08-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-01 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2017-04-28 | - | Årsstämma |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-12 | - | Kvartalsrapport 2016-Q1 |
| 2016-05-02 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2016-04-29 | - | Årsstämma |
| 2016-03-31 | - | Bokslutskommuniké 2015 |
| 2016-02-24 | - | Split PEG 1:10 |
| 2016-02-18 | - | Extra Bolagsstämma 2016 |
| 2015-10-21 | - | Kvartalsrapport 2015-Q3 |
| 2015-07-15 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-01 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2015-04-30 | - | Årsstämma |
| 2015-04-14 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-31 | - | Bokslutskommuniké 2014 |
| 2015-02-02 | - | Extra Bolagsstämma 2015 |
| 2014-12-22 | - | Extra Bolagsstämma 2014 |
| 2014-11-07 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-15 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-09 | - | Kvartalsrapport 2014-Q1 |
| 2014-04-30 | - | Årsstämma |
| 2014-04-01 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2014-03-31 | - | Bokslutskommuniké 2013 |
| 2013-11-06 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-16 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-07 | - | Kvartalsrapport 2013-Q1 |
| 2013-04-30 | - | Årsstämma |
| 2013-04-01 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2013-03-29 | - | Bokslutskommuniké 2012 |
| 2012-11-06 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-17 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-07 | - | Kvartalsrapport 2012-Q1 |
| 2012-05-01 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2012-04-30 | - | Årsstämma |
| 2012-03-30 | - | Bokslutskommuniké 2011 |
| 2011-11-04 | - | Extra Bolagsstämma 2011 |
| 2011-05-02 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2011-04-29 | - | Årsstämma |
| 2010-05-03 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Small Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2024-10-04 09:01:25
| Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights 4. October 2024 Company Announcement no. 24 | |
| With reference to company announcement no. 19, on 3 June 2024, the extraordinary general meeting in Pharma Equity Group A/S approved a reduction of the company's share capital by a nominal value of DKK 920,667,494.70 from a nominal value of DKK 1,022,963,883.00 to a nominal value of DKK 102,296,388.30 by allocation to a specific reserve pursuant to section 188(1)(3) of the Danish Companies Act. The capital reduction has today been finally registered with the Danish Business Authority and has been carried out by way of a proportional reduction of the denomination of all the company's shares, meaning that the denomination of the shares is reduced from DKK 1.00 to DKK 0.1. Nasdaq Copenhagen has been informed about the capital reduction which will be effected in Nasdaq Copenhagen's systems soonest possible. Pharma Equity Group A/S' updated articles of associations can be found at the company's website. In accordance with section 32 of the Danish Capital Markets Act, Pharma Equity Group A/S hereby announces that its share capital then amounts to a nominal value of DKK 102,296,388.30, corresponding to 1,022,963,883 shares of nominally DKK 0.1 each and a total of 1,022,963,883 voting rights. For further information, please contact: | |
| Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: +45 4022 2114 Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone: +45 2622 7222 | |
| About Pharma Equity Group A/S Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects. The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth. |